Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Mucormycosis secondary prevention
Introduction
Overview
Overview
Posaconazole has been found to be an effective agent for secondary prevention of mucormycosis.
Secondary Prevention in Mucormycosis
Secondary Prevention in Mucormycosis
- Patients who respond to a parenteral lipid amphotericin B-based treatment, given for at least 3 weeks, are transitioned to oral posaconazole as maintenance/secondary prophylaxis with serial monitoring of posaconazole serum drug concentrations to ensure compliance and absorption of the antifungal.[1]
- Lipid amphotericin B may achieve high levels in the human tissues, thus, intermittent doses of lipid amphotericin B (i.e., 5 mg/kg 3 times per week or possibly even 2 times per week) after at least 3 to 4 weeks of initial therapy as an alternative to posaconazole therapy may also be used.
References
References
- ↑ Kontoyiannis DP, Lewis RE (2011). “How I treat mucormycosis”. Blood. 118 (5): 1216–24. doi:10.1182/blood-2011-03-316430. PMC 3292433. PMID 21622653.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]